Are Social Media Short Sellers Calling for a Pullback?
The August 31 short interest data have been compared with the previous report. Short interest in most of these selected social media stocks increased.
All Work
Chris Lange
Short Sellers Focus Even More on Major Semiconductors
The August 31 short interest data have been compared with the previous report. Short interest increased in most of these selected semiconductor stocks.
Short Sellers Hike Bets in Major Biotechs
The August 31 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks increased.
Short Sellers Run for Cover From Major Oil
The August 31 short interest data have been compared with the previous figures, and short interest moves for most of the selected oil stocks were downward.
Major Pharma Short Interest Surges
The August 31 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
Tuesday’s Biggest Winners and Losers in the S&P 500
Tuesday was another positive day for the U.S. broad markets with all major averages posting a gain. Crude oil was positive on the day and helped lift Oil & Gas stocks. Practically all of…
Meet Apple’s Newest iPhone
The Apple 10 year anniversary for the iPhone is underway and we have already seen some incredible developments. Not only is the new Apple campus impressive but the Apple Watch broke the mold as…
What Apple’s iOs Might Say About the New iPhone
There was a leak in regards to the newest iPhone operating system (iOS), and it gave some insight to what we can expect from this soon-to-be trillion-dollar company.
BioCryst Pharmaceuticals Announces Secondary Offering
BioCryst Pharmaceuticals watched its shares fall handily on Tuesday after the firm announced a secondary offering.
Sage Therapeutics Gets a Dunce Hat
Sage Therapeutics saw its shares drop by about a quarter early on Tuesday after the firm gave an update on its late-stage study trial in the treatment super-refractory status epilepticus.
Monday’s Biggest Winners and Losers in the S&P 500
Monday was an exception day for the U.S. broad markets with all three major indices up. In fact, the market had its best day since earlier March of this year. Crude oil posted a…
Why Jefferies Sees 5 Big Winners From This Hurricane Season
A few companies dealing in the areas affected by Hurricanes Harvey and Irma stand to win handily from this hurricane season, according to Jefferies.
Can a New CEO Turn Around Teva?
Often companies that lose their way or face adversity may need a change at the top. Teva Pharmaceutical seems to be the perfect example, and with its change investors are sending the shares much…
Marinus Pharma Wins Big With Mid-Stage Epilepsy Study
Marinus Pharmaceuticals saw its shares make a huge gain to kick off the week after the firm announced top-line results from its mid-stage study in patients with CDKL5 disorder.
Despegar Finally Prices IPO
Despegar.com intends to price more than 12 million shares in a range that results in an initial public offering valued up to almost $382 million.
Achillion Pharma Slides After Hep C Deal Is Terminated
Achillion Pharmaceuticals saw its shares slump early on Monday after the firm announced that its hepatitis C license and collaboration agreement with Janssen had been terminated.
5 Stocks That Tanked the Dow Last Week
The Dow Jones Industrial Average just had its worst weekly drop since March. Here’s a look at the stock brought the index down over this past week.
Tech Analyst Calls That Absolutely Cannot Be Ignored
24/7 Wall St. has put together a look at a few widely influential analyst calls over this past week on some of the biggest names in the tech sector.
Why Zumiez Earnings Are So Great
Zumiez shares were up sharply since it reported its fiscal second-quarter financial results after the markets closed Thursday.
Kura Oncology Doubles on Mid-Stage Trial Results
Kura Oncology saw its shares double early Friday after the firm announced results from its mid-stage trial in patients with squamous cell carcinomas.